Serologic features of primary Sjögren’s syndrome: clinical and prognostic correlation

Garcı́a-Carrasco, Mario; Mendoza‐Pinto, Claudia; Jiménez-Hernández, César; Jiménez-Hernández, Mario; Nava-Zavala, Arnulfo Hernán; Riebeling, Carlos

doi:10.2217/ijr.12.64

Cited by 34 publications

(22 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also studied patients with SS, since they can exhibit numerous autoantibodies and low serum complement levels . We observed an increased frequency of positive CB‐CAPs compared to low serum complement levels (10% versus 2%) in SS patients, but these were not significantly different from frequencies in the control group with other rheumatic diseases.…”

Section: Discussionmentioning

confidence: 81%

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus

Ramsey‐Goldman

Alexander²,

Massarotti

et al. 2019

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective To evaluate the frequency of cell‐bound complement activation products (CB‐CAPs) as a marker of complement activation in patients with suspected systemic lupus erythematosus (SLE) and the usefulness of this biomarker as a predictor of the evolution of probable SLE into SLE as classified by the American College of Rheumatology (ACR) criteria. Methods Patients in whom SLE was suspected by lupus experts and who fulfilled 3 ACR classification criteria for SLE (probable SLE) were enrolled, along with patients with established SLE as classified by both the ACR and the Systemic Lupus International Collaborating Clinics (SLICC) criteria, patients with primary Sjögren's syndrome (SS), and patients with other rheumatic diseases. Individual CB‐CAPs were measured by flow cytometry, and positivity rates were compared to those of commonly assessed biomarkers, including serum complement proteins (C3 and C4) and autoantibodies. The frequency of a positive multianalyte assay panel (MAP), which includes CB‐CAPs, was also evaluated. Probable SLE cases were followed up prospectively. Results The 92 patients with probable SLE were diagnosed more recently than the 53 patients with established SLE, and their use of antirheumatic medications was lower. At the enrollment visit, more patients with probable SLE were positive for CB‐CAPs (28%) or MAP (40%) than had low complement levels (9%) (P = 0.0001 for each). In probable SLE, MAP scores of >0.8 at enrollment predicted fulfillment of a fourth ACR criterion within 18 months (hazard ratio 3.11, P < 0.01). Conclusion Complement activation occurs in some patients with probable SLE and can be detected with higher frequency by evaluating CB‐CAPs and MAP than by assessing traditional serum complement protein levels. A MAP score above 0.8 predicts transition to classifiable SLE according to ACR criteria.

show abstract

Section: Discussionmentioning

confidence: 81%

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus

Ramsey‐Goldman

Alexander²,

Massarotti

et al. 2019

Arthritis & Rheumatology

View full text Add to dashboard Cite

show abstract

“…However, although the active phase of SLE is commonly characterized by hypocomplementemia, about 12% of SS cases also present with hypocomplementemia, which in SS is associated with increased mortality (26), and thus careful attention was needed for the patient during followup. In addition, hypocomplementemia is sometimes observed in SLE-associated SS.…”

Section: Discussionmentioning

confidence: 99%

Successful Detection of Renal Involvement in Sjögren's Syndrome Secondary to Systemic Lupus Erythematosus by Renal Biopsy

et al. 2015

View full text Add to dashboard Cite

An 80-year-old man presented with a mildly decreased renal function and increased anti-double-stranded-DNA (anti-dsDNA) antibody levels, and met the diagnostic criteria of the American College of Rheumatology for systemic lupus erythematosus (SLE). However, the incremental increase in creatinine levels and the mild proteinuria were inconsistent with lupus nephritis. We performed a renal biopsy, which revealed interstitial nephritis and minor glomerular abnormalities. Further examinations determined that the renal lesion was due to Sjögren's syndrome secondary to SLE. Following treatment with oral prednisolone, the patient's renal function improved as his anti-dsDNA antibody levels decreased. This case report indicates that renal biopsy should be considered even in elderly individuals when it may assist in the diagnosis, treatment, and prognosis of the patient.

show abstract

“…Methods: The present retrospective longitudinal cohort study included patients with LN and reduced renal function. Reduced renal function was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 . Recovery of renal function was determined by eGFR >60 mL/min/ 1.73 m 2 at 6 months after baseline, and factors associated with it were evaluated using logistic regression analysis.…”

Section: Subpopulation Composition Of Inflammatory Infiltrates Of Thementioning

confidence: 99%

Fri0244 mathematical Processing Is Affected by Daily but Not Cumulative Glucocortocoid Dose in Patients With Systemic Lupus Erythematosus (Sle)

Mak

Teo²,

Kow

et al. 2019

Poster Presentations

View full text Add to dashboard Cite

Background:The impact of glucocorticoids on neurocognitive performance in patients with SLE is not fully understood.Objectives:We aimed to study the effect of daily and cumulative doses of glucocorticoids on neurocognitive performance in patients with SLE using the computer-based Automated Neuropsychological Assessment Matric (ANAM).Methods:Consecutive patients with SLE and gender- and age-matched (±5 years) healthy control subject (HC) were studied. In a quiet and comfortable room, each subject underwent the 45-minute ANAM test under supervision which comprises simple reaction time (SRT) that probes neuromuscular efficiency, and 8 domains of neurocognitive assessment including 3 code substitution tests (probing learning and recall), spatial processing (probing visual perception and mental rotation), matching to sample (probing short-term memory and attention), continuous performance test (probing sustained attention), mathematical processing, and memory search (probing working memory). Anxiety and depression were assessed by the Hospital Anxiety and Depression scale (HADS). The total and individual-domain throughput scores (TPS) were compared between both groups using Student’s t test. The presence of cognitive dysfunction, defined as total TPS <1.5 SD below the mean TPS of HC, was compared between both groups by χ2 test. Within the SLE group, the relationships between prednisolone dose (daily [mg] or cumulative [gm]) and individual-domain TPS were first explored by bivariate correlations. Independent association between glucocorticoid dose and individual-domain TPS that showed significant bivariate associations with prednisolone dose was determined by multiple linear regression, with adjustment for potential clinically- and demographically-important cofounders.Results:Ninety-six SLE patients and 96 HC were studied, 16 men (16.7%) were present in each group. The mean age±SD of SLE patients and HC were 36.57±11.4 and 33.61±10.6 years (p=0.073), respectively. The mean±SD duration of SLE, SLEDAI and daily and cumulative prednisolone doses were 98.85±87.4 months, 3.37±3.4, 11.01±13.6mg and 16.92±18.5gm, respectively. SLE patients had a significantly higher mean HADS-anxiety score than HC (6.25±3.3 vs 4.62±3.0, p=0.001) while the mean HADS-depression score was comparable between both groups (p=0.093). SLE patients had significantly shorter duration of education (12.92±3.92 vs 15.86±2.5 years, p<0.001), scored significantly worse across all the 8 ANAM domains, had a significantly lower mean total TPS [337.23±94.4 vs 395.62±87.6, p<0.001) and were significantly more prevalent of cognitive dysfunction as compared to HC (25.0% vs 7.3%, p=0.001). In SLE patients, a statistically significant negative correlation was found between daily prednisolone dose and TPS of mathematical processing (r=-0.248, p<0.015), while no significant correlation between cumulative glucocorticoid dose and any of the individual ANAM domain was found. In multivariate regression, daily prednisolone dose remained independently associated with lower T...

show abstract

Serologic features of primary Sjögren’s syndrome: clinical and prognostic correlation

Cited by 34 publications

References 51 publications

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus

Successful Detection of Renal Involvement in Sjögren's Syndrome Secondary to Systemic Lupus Erythematosus by Renal Biopsy

Fri0244 mathematical Processing Is Affected by Daily but Not Cumulative Glucocortocoid Dose in Patients With Systemic Lupus Erythematosus (Sle)

Contact Info

Product

Resources

About

Serologic features of primary Sjögren’s syndrome: clinical and prognostic correlation

Cited by 34 publications

References 51 publications

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus

Successful Detection of Renal Involvement in Sj&ouml;gren's Syndrome Secondary to Systemic Lupus Erythematosus by Renal Biopsy

Fri0244 mathematical Processing Is Affected by Daily but Not Cumulative Glucocortocoid Dose in Patients With Systemic Lupus Erythematosus (Sle)

Contact Info

Product

Resources

About

Successful Detection of Renal Involvement in Sjögren's Syndrome Secondary to Systemic Lupus Erythematosus by Renal Biopsy